W. Walker, M. Hamburger
Oct 1, 1957
Citations
0
Influential Citations
5
Citations
Journal
Annals of the New York Academy of Sciences
Abstract
Sulfamethoxypyridazine (Kynext) has been shown to have antibacterial activity approximately equivalent to that of sulfadiazine. However, it possesses certain additional characteristics that make it more desirable for clinical usage. I t is well absorbed from the gastrointestinal tract, poorly acetylated, excreted very slowly, and quite soluble in urine. Frisk and Wassen' and Nichols el a1.2 have demonstrated significant blood levels for 4 days following a single 4.0-gm. dose, 15 per cent or less of the drug being acetylated. However, from 35 to 60 per cent of the amount excreted was in the conjugated form. No signs of renal or hematological toxicity have been reported, although an occasional patient experienced headache and malaise, and a few instances of skin rash have been noted. Sulfamethoxypyridazine was used in the treatment of 16 cases of acute pyelonephritis or acute exacerbation of chronic pyelonephritis in dosages of 1.0 to 2.0 gm. initially, and maintenance doses of 1.0 gm. once a day, 1.0 gm. twice daily, or 0.5 gm. twice a day. No significant differences were observed in clinical response to these different schedules.